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severity of the late complications were not different between 
the experimental group and the control group, p=0.54; the 
overall toxicity rate being respectively 20% vs. 21% and for 
grade III+ complications 9% vs. 6%. 
 
Conclusion: The trial showed no difference in local efficacy 
between preoperative 5x5 Gy with consolidation 
chemotherapy and standard preoperative chemoradiation. 
Lower acute toxicity, lower cost, convenience and a trend 
towards improved overall survival favour 5x5 Gy with 
consolidation chemotherapy. 
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Purpose or Objective: The aim of the ACCORD 12 trial was to 
compare two different regimens of neoadjuvant 
chemoradiotherapy (nCRT). No significant difference has 
been found in main end point (pCR rate) . At 3 years there 
was no significant difference for local control and survival. 
We report the 5 years outcome. 
 
Material and Methods: Between 11/2005- 07/2008, 598 pts 
randomized. Inclusion criteria: adenocarcinoma , distal- 
middle rectum, T3-4, anterior-distal T2 staged using MRI 
and/or endorectal US. Treatment : CAP 45 : radiotherapy 
(RT) 45 Gy/25 fr/5 weeks with concurrent capecitabine (800 
mg/m2 BID) vs CAPOX 50 : RT 50 Gy/25 fr/5 weeeks with 
Capecitabine (same) and weekly oxaliplatin (50 mg/m2). A 
TME surgery was performed after 6 weeks interval. Adjuvant 
chemotherapy was left to each institution. 
 
Results: Median follow-up time was 60 months with 299 pts in 
each group. In intent to treat analysis main results are shown 
in table. In 31 pts T4 confounded the local relapse rate was 
11.3%[3.8-31.5].A clinical CR in 24 pts was associated with 
81% DFS (p<0.0001) and Sphincter saving or organ 
preservation in 23. Adjuvant chemotherapy given in 253 pts. 
 
Endpoint CAP 45 299 pts 
CAPOX 50 
299 pts p(log rank) 
HR 
CI 95% 
Loc. Rec. 5y 8.8% 7.8% 0.78% 0.92 [0.51-1.66] 
Dist. Met. 5y 30% 28% 0.48% 0.89 [0.77-1.15] 
DFS 5y 60.4% 64.7% 0.25% 0.86 [0.66-1.11] 
Overall Surv. 5y 76.4% 81.9% 0.06% 0.71 [0.50-1.01] 
Bowel function (1-7) 5.2 4.9 NS  
 
Conclusion: At 5 years there was no significant difference for 
local recurrence, distant metastases, survival and bowel 
function rates. Both CAP 45 and CAP 50 regimens are feasible 
and provide acceptable local control rate. More prognostic 
factors will be available at time of meeting and may generate 
hypothesis to further improve local control in locally 
advanced T3 or T4, achieve organ preservation in some T2 or 
early T3 and reduce toxicity in pts > 75 y old. Gerard Jp et 
al. J Clin Oncol. 2012 Dec 20;30(36):4558-65 
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Purpose or Objective: The 5-year local control and survival 
results of the GEC-ESTRO multicentric accelerated partial 
breast irradiation (APBI) trial have been reported recently. In 
this analysis we report the 5-year late toxicity and cosmetic 
results of patients treated with APBI using interstitial 
brachytherapy (iBT) compared to those who underwent 
standard whole breast irradiation (WBI) with a tumour bed 
boost. 
 
Material and Methods: Between April 2004 and July 2009, 
1184 patients aged ≥40 years with stage 0, I and IIA breast 
cancer who underwent breast conserving surgery (BCS) were 
randomly assigned to receive either 50 Gy WBI with tumour 
bed boost of 10 Gy or APBI using HDR/PDR iBT. Among these, 
5-year follow-up records on late toxicities and cosmetic 
results were available at 969 patients (82%). Five-year 
prevalences of toxicities graded by the RTOG/EORTC late 
radiation morbidity scoring scheme were compared using the 
Fisher’s exact test. The cosmetic results were scored by the 
patients and treating radiation oncologists using the four-
scale (excellent-good-fair-poor) Harvard criteria. The trial is 
registered with ClinicalTrials.gov, NCT00402519. 
 
Results: There were no grade 4 toxicities. The cumulative 
incidence of grade (G) 2-3 late skin toxicity at 5 years was 
5.7% in the WBI group versus 3.2% in the APBI group (p=0.08), 
difference: -2.4% (95% CI: -5 – 0.2%). Concerning G2-3 late 
subcutaneous tissue side effects at 5 years the cumulative 
risk was 6.3% in the WBI group versus 7.6% in the APBI group 
(p=0.53), difference: 1.3% (95% CI: -1.9 – 4.5%). The 
cumulative incidence of severe (G3) fibrosis at 5 years was 
0.2% in the WBI group and 0% in the APBI group (p=0.46), 
difference: -0.2% (95% CI: -0.6 – 0.2%). The cumulative 
incidence of G2-3 breast pain was low in both arms (3.2% 
